Catalyst Pharmaceutical CPRX Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $709.17M+37.0% | $517.55M+276% | $137.64M-53.9% | $298.4M+74.0% | ||
| $126.48M+93.2% | $65.48M+22.4% | $53.51M+413% | $10.44M+57.7% | ||
| $37.17M+90.2% | $19.54M+24.9% | $15.64M+130% | $6.81M-13.5% | ||
| $894.03M+43.4% | $623.61M+184% | $219.33M-31.6% | $320.81M+52.7% | ||
| $1.04M-23.4% | $1.35M+13.3% | $1.2M+41.1% | $847K-11.7% | ||
| $131.67M-16.0% | $156.67M-19.3% | $194.05M+498% | $32.47M— | ||
| $22.54M+4.5% | $21.56M+30.8% | $16.49M— | $0— | ||
| $1.1B+29.7% | $851.41M+81.1% | $470.11M+25.2% | $375.63M+58.0% | ||
| $11.2M-32.5% | $16.59M+12.2% | $14.8M+272% | $3.98M+43.6% | ||
| $147.15M+21.9% | $120.68M+58.7% | $76.06M+32.1% | $57.59M+113% | ||
| $149.71M+21.0% | $123.78M+50.5% | $82.23M+9.3% | $75.21M+143% | ||
| $123K+1.7% | $121K+13.1% | $107K+1.9% | $105K+1.9% | ||
| $474.19M+66.3% | $285.16M+135% | $121.27M+143% | $49.86M+290% | ||
| $954.27M+31.1% | $727.63M+87.6% | $387.88M+29.1% | $300.42M+45.2% | ||
| $1.1B+29.7% | $851.41M+81.1% | $470.11M+25.2% | $375.63M+58.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Catalyst Pharmaceutical's total assets?
- Catalyst Pharmaceutical (CPRX) holds $1.1B in total assets, up 26.3% year over year.
- How much debt does Catalyst Pharmaceutical have?
- Catalyst Pharmaceutical carries $2.7M in total debt against $1.0B of shareholders' equity, a debt-to-equity ratio of 0.00.
- How much cash does Catalyst Pharmaceutical have?
- Catalyst Pharmaceutical holds $755.9M in cash and equivalents.
- Can Catalyst Pharmaceutical cover its short-term obligations?
- Its current ratio is 7.10 — current assets exceed current liabilities.
- Where does Catalyst Pharmaceutical's balance sheet data come from?
- Every line is extracted from Catalyst Pharmaceutical's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
